These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 16404937

  • 1. [Oral cavity manifestations of gastroesophageal reflux disease].
    Maev IV, Barer GM, Busarova GA, Pustovoĭt EV, Polikanova EN, Burkov SG, Gurenev GL.
    Klin Med (Mosk); 2005; 83(11):33-8. PubMed ID: 16404937
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
    Khavkin AI, Zhikhareva NS, Rachkova NS, Babaian ML, Volynets GV, Khanakaeva ZK.
    Eksp Klin Gastroenterol; 2004; (2):53-6. PubMed ID: 15462323
    [No Abstract] [Full Text] [Related]

  • 4. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW, Goh KL.
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [Abstract] [Full Text] [Related]

  • 5. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ, Hunt RH.
    Yale J Biol Med; 1999 Sep; 72(2-3):181-94. PubMed ID: 10780580
    [Abstract] [Full Text] [Related]

  • 6. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J, Dodd S, Durkin M, Sloan S.
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [Abstract] [Full Text] [Related]

  • 7. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M, Iwakiri R, Fujimoto K, Fujiwara Y, Inamori M, Tanaka J, Shimatani T, Akiyama J, Ando T, Manabe N, Kinjo F, Deguchi R, Kusano M.
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [Abstract] [Full Text] [Related]

  • 8. [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
    Maev IV, Kucheriavyĭ IuA, Danilin MS.
    Eksp Klin Gastroenterol; 2003 Nov; (5):10-2, 192. PubMed ID: 14621603
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough.
    Ours TM, Kavuru MS, Schilz RJ, Richter JE.
    Am J Gastroenterol; 1999 Nov; 94(11):3131-8. PubMed ID: 10566703
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Some comparative aspects of treating the gastroesophageal reflux disease eradication].
    Minushkin ON, Maslovskiĭ LV, Anikina NIu.
    Eksp Klin Gastroenterol; 2004 Nov; (3):45-8, 104. PubMed ID: 15560401
    [Abstract] [Full Text] [Related]

  • 13. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, Vaezi MF.
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [Abstract] [Full Text] [Related]

  • 14. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J.
    Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
    [Abstract] [Full Text] [Related]

  • 15. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR.
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
    [Abstract] [Full Text] [Related]

  • 16. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
    Katzka DA, Paoletti V, Leite L, Castell DO.
    Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M, Chiba T, Kinoshita Y, ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP.
    Aliment Pharmacol Ther; 2007 Jul 01; 26(1):69-77. PubMed ID: 17555423
    [Abstract] [Full Text] [Related]

  • 19. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M, Miwa H, Kusano M, J-FAST group.
    J Gastroenterol Hepatol; 2012 May 01; 27(5):913-8. PubMed ID: 22142515
    [Abstract] [Full Text] [Related]

  • 20. [Significance of PPI-test in the diagnosis of GERD].
    Takahashi M, Nishiki R, Ichimura H, Takada H, Kuwayama H.
    Nihon Rinsho; 2004 Aug 01; 62(8):1465-74. PubMed ID: 15344536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.